<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31650" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperbaric Zygomycotic Infections</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Quandahl</surname>
            <given-names>Rachel</given-names>
          </name>
          <aff>Nebraska Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jan</surname>
            <given-names>Abdul H.</given-names>
          </name>
          <aff>Windsor University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cooper</surname>
            <given-names>Jeffrey S.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rachel Quandahl declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdul Jan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeffrey Cooper declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31650.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Invasive zygomycosis, or mucormycosis, are a group of infections caused by fungi in the order Mucorales. The most common species that cause infection are the Rhizopus species from the Mucoraceae family. The disease is aggressive and commonly fatal despite appropriate treatment. Infection with mucormycosis is extremely rare in healthy individuals; infections occur almost exclusively in immunocompromised patients. It has an especially high predilection in diabetics who are in ketoacidosis, as the acidic environment contributes to fungal growth. This activity reviews the presentation of zygomycosis and highlights the role of the interprofessional team in the management of patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology zygomycosis.</p></list-item><list-item><p>Outline the presentation of a patient with zygomycosis.</p></list-item><list-item><p>Summarize the treatment and management options available for zygomycosis.</p></list-item><list-item><p>Outline interprofessional team strategies to optimize care coordination and care delivery to advance the diagnosis and treatment of zygomycosis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31650&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31650">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31650.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Invasive zygomycosis, or mucormycosis, are a group of infections caused by fungi in the order&#x000a0;<italic toggle="yes">Mucorales</italic>. The most common species that cause infection are the&#x000a0;<italic toggle="yes">Rhizopus</italic>&#x000a0;species from the&#x000a0;<italic toggle="yes">Mucoraceae</italic>&#x000a0;family. The disease is highly aggressive and commonly fatal despite appropriate treatment. It is extremely rare for mucormycosis to occur in healthy individuals. It almost always affects the immunocompromised- especially people with diabetes who are in ketoacidosis as acidic environment contributes to fungal growth.<xref ref-type="bibr" rid="article-31650.r1">[1]</xref><xref ref-type="bibr" rid="article-31650.r2">[2]</xref><xref ref-type="bibr" rid="article-31650.r3">[3]</xref></p>
      </sec>
      <sec id="article-31650.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>These organisms are ubiquitous. They are found outdoors in soil and vegetation. They are also a common mold found in homes. One study from Denmark showed that it was present in 98% of samples taken from house dust. Studies have also shown the mold to be present on molded bread, other foods, dirty carpets, and vacuum cleaner systems.<xref ref-type="bibr" rid="article-31650.r4">[4]</xref></p>
      </sec>
      <sec id="article-31650.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Aggressive zygomycotic infections occur in immunocompromised individuals. Most commonly, they tend to occur in uncontrolled diabetics, especially those with ketoacidosis. They also occur in patients with malignancies, hematologic disorders, transplants, burns, or those receiving immunosuppressive medications.&#x000a0;For reasons unknown, two-thirds of zygomycosis occurs in males. The occurrence is equal across race, age, and geography.</p>
      </sec>
      <sec id="article-31650.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Mucormycosis, especially when caused by&#x000a0;<italic toggle="yes">Rhizopus arrhizus,&#x000a0;</italic>is an acute and rapidly fatal disease. These organisms can invade blood vessels and cause destruction quickly. The infection rapidly accelerates and extends into adjacent tissues and structures. Necrotic and black tissue develops in the nares, palate, or orbit. The organisms can invade vessels and initiate a clotting response that leads to infarction. This tissue death leads to acidosis, which continues to feed the growth and destruction of the fungal organisms. This lack of blood flow also makes treatment with antifungals more difficult. Due to angioinvasion, the infection can quickly progress to fungemia and the disseminated form.</p>
      </sec>
      <sec id="article-31650.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>A biopsy of the affected tissue will show broad, nonseptate hyphae with right-angle branching.</p>
      </sec>
      <sec id="article-31650.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>There are several different classifications of zygomycosis: rhinocerebral, pulmonary, gastrointestinal, cutaneous, and disseminated. Rhinocerebral is the most common form and initially resembles sinusitis with congestion, sinus pain, and drainage. The exam will vary depending on how advanced the infection is. Patients may present with erythema, periorbital swelling, and black necrotic eschars. History and physical will also vary depending on the underlying immunosuppressive disorder. For example, a patient with diabetic ketoacidosis may present with nausea, vomiting, and abdominal pain.</p>
      </sec>
      <sec id="article-31650.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The current standard of care for treatment includes aggressive surgical debridement and treatment with liposomal amphotericin B. If there is any suspicion for mucormycosis, amphotericin B should be initiated immediately. Correction of any underlying pathophysiology, such as diabetic ketoacidosis, should be done as well.<xref ref-type="bibr" rid="article-31650.r5">[5]</xref><xref ref-type="bibr" rid="article-31650.r6">[6]</xref><xref ref-type="bibr" rid="article-31650.r7">[7]</xref></p>
        <p>Hyperbaric oxygen therapy (HBO) is commonly used for necrotizing soft tissue infections, chronic osteomyelitis, and compromised grafts and flaps. Hypoxia is a problem when it comes to nonhealing tissue. HBO allows for saturation of oxygen within the blood and hemoglobin and a 10-fold increase of dissolved oxygen in plasma. Oxygen delivery to compromised tissue is increased, and normal tissue oxygenation for healing is restored. Hyperbaric oxygen therapy has also been shown to improve vascularity and stimulate new blood vessel growth. These factors are important in zygomycosis because of the angioinvasive nature of the infection, tissue becomes hypoxic and blood vessels become thrombosed.&#x000a0;In addition, zygomycosis patients often undergo extensive debridement surgery. In cases of rhinocerebral mucormycosis, patients can be left disfigured. Addition of postsurgical hyperbaric oxygen therapy could help the formation of granulation tissue and bone healing.<xref ref-type="bibr" rid="article-31650.r8">[8]</xref><xref ref-type="bibr" rid="article-31650.r9">[9]</xref><xref ref-type="bibr" rid="article-31650.r10">[10]</xref></p>
        <p>Due to the rareness and severity of this rapidly progressive infection, it is extremely difficult to conduct randomized, controlled trials on human patients. Therefore, most of the research on using hyperbaric oxygen therapy for zygomycosis largely relies on case reports and retrospective studies.&#x000a0;In a review of the literature done by Ferguson&#x000a0;et al., 12 patients with rhinocerebral mucormycosis were investigated. They were all treated with surgery and amphotericin B. Half of the patients were treated with adjunctive hyperbaric oxygen therapy. Of the patients who did not receive HBOT, 4 out of the 6 patients died because of the infection. Of the 6 patients who received adjunctive HBOT, only 2 died. However, this case review is too small to draw any statistical conclusions.</p>
        <p>One of the most interesting case reports comes from Couch&#x000a0;et al<italic toggle="yes">.&#x000a0;</italic>in which 2 diabetic patients with rhinocerebral mucormycosis were treated with adjunctive HBOT. A high fatality rate occurs when the cerebral extension of the infection occurs. Both patients were critically ill and had aggressive brain mucor abscesses and one patient even had total occlusion of the internal carotid artery. Despite surgical debridement and medical therapy, their infections progressed and HBOT was added as salvage therapy. Both patients had marked clinical improvement upon addition of HBOT. They each received treatments 6 days a week at 2.5 ATA for 90 minutes. One received 79 total treatments and the other received 85 treatments. Both patients remained disease-free 21 months after discharge. De La Paz&#x000a0;et al. and Melero&#x000a0;et al.&#x000a0;also published case reports on successfully treating bilateral rhinocerebral mucormycosis with adjunctive HBO therapy.&#x000a0;A more recent review of cases done in 2004 by John BV&#x000a0;et al.&#x000a0;explored the use of hyperbaric oxygen therapy in 28 cases. The HBO treatment sessions 90 minutes long at a pressure of 2 to 3 ATA, ranging from 90 to 120 minutes. In general, HBOT was not started until after surgical debridement. The survival rate was 86% with diabetic patients having a much higher survival rate of 94%. There is a higher rate of survival when the underlying condition is correctable such as diabetic ketoacidosis. Conversely, 2 out of the 3 patients with malignancies died because of the infection.</p>
        <p>Considering the pathophysiology of invasive zygomycosis, its high morbidity and mortality, and the benefits of hyperbaric oxygen treatment, it is reasonable to consider HBOT as adjunctive therapy in the treatment of this disease.</p>
      </sec>
      <sec id="article-31650.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Actinomycosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anthrax</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Aspergillosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Brain abscess</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cryptococcosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cellulitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colonic obstruction</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ecthyma gangrenosum</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fusariosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nocardiosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31650.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Even with prompt diagnosis and treatment, overall mortality rates average about 50%. Rhino-orbital-cerebral mucormycosis carries a much higher mortality rate. Some studies report anywhere from 30% to 80% depending on the underlying condition. Mortality is higher in patients who have hematological disorders or malignancies as their underlying conditions are more difficult to treat. The disseminated form has a mortality of over 90%. Patients who do survive are often left disfigured due to extensive debridement surgeries.</p>
      </sec>
      <sec id="article-31650.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Mucormycosis is a life-threatening infection that is best managed by an interprofessional team that includes a pathologist, laboratory specialist, internist, infectious disease expert, ICU nurses, and a surgeon. These patients need immediate treatment and debridement of the necrotic tissues. HBO is used but only in stable patients. Antifungal agents need to be administered intravenously for weeks but despite optimal treatment, the infection carries a mortality of more than 50%.<xref ref-type="bibr" rid="article-31650.r11">[11]</xref><xref ref-type="bibr" rid="article-31650.r12">[12]</xref><xref ref-type="bibr" rid="article-31650.r13">[13]</xref></p>
      </sec>
      <sec id="article-31650.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31650&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31650">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/hyperbaric-zygomycotic-infections-hyperbaric-mucormycosis-infections/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31650">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31650/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31650">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31650.s13">
        <title>References</title>
        <ref id="article-31650.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaideeswar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Zygomycotic infective endocarditis in pregnancy.</article-title>
            <source>Cardiovasc Pathol</source>
            <year>2017</year>
            <season>May-Jun</season>
            <volume>28</volume>
            <fpage>28</fpage>
            <page-range>28-30</page-range>
            <pub-id pub-id-type="pmid">28288409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mineta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Obata</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Zygomycotic invasion of the central nervous system.</article-title>
            <source>Jpn J Radiol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>376</fpage>
            <page-range>376-80</page-range>
            <pub-id pub-id-type="pmid">20585927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Culpepper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Primary renal zygomycotic infarction mimicking renal neoplasia in an immunocompetent patient.</article-title>
            <source>Am J Med Sci</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>338</volume>
            <issue>4</issue>
            <fpage>330</fpage>
            <page-range>330-3</page-range>
            <pub-id pub-id-type="pmid">19701078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vasishta</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Rajesh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pattari</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Zygomycotic necrotizing fasciitis in immunocompetent patients: a series of 18 cases.</article-title>
            <source>Mod Pathol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>1221</fpage>
            <page-range>1221-6</page-range>
            <pub-id pub-id-type="pmid">16741524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jenks</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hoenigl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?</article-title>
            <source>Med Mycol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>57</volume>
            <issue>Supplement_2</issue>
            <fpage>S168</fpage>
            <page-range>S168-S178</page-range>
            <pub-id pub-id-type="pmid">30816967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koehler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mellinghoff</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lagrou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alanio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arenz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoenigl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koehler</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Lass-Fl&#x000f6;rl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meis</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cornely</surname>
                <given-names>OA</given-names>
              </name>
            </person-group>
            <article-title>Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2019</year>
            <month>Jun</month>
            <day>01</day>
            <volume>74</volume>
            <issue>6</issue>
            <fpage>1704</fpage>
            <page-range>1704-1712</page-range>
            <pub-id pub-id-type="pmid">30770712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durga</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Soneja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xess</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jorwal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nischal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ranjan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wig</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Invasive fungal infections in critically ill patients: A prospective study from a tertiary care hospital in India.</article-title>
            <source>Drug Discov Ther</source>
            <year>2018</year>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>363</fpage>
            <page-range>363-367</page-range>
            <pub-id pub-id-type="pmid">30674771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoenigl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gangneux</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alanio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Govender</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Klimko</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Meis</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Pasqualotto</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Seidel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Lagrou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lass-Fl&#x000f6;rl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cornely</surname>
                <given-names>OA</given-names>
              </name>
              <collab>European Confederation of Medical Mycology (ECMM)</collab>
            </person-group>
            <article-title>Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together.</article-title>
            <source>Mycoses</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>61</volume>
            <issue>11</issue>
            <fpage>885</fpage>
            <page-range>885-894</page-range>
            <pub-id pub-id-type="pmid">30086186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jenks</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Salzer</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Prattes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Buchheidt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoenigl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>1033</fpage>
            <page-range>1033-1044</page-range>
            <pub-id pub-id-type="pmid">29750016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skiada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lass-Floerl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klimko</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roilides</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Petrikkos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Challenges in the diagnosis and treatment of mucormycosis.</article-title>
            <source>Med Mycol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>56</volume>
            <issue>suppl_1</issue>
            <fpage>93</fpage>
            <page-range>93-101</page-range>
            <pub-id pub-id-type="pmid">29538730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Gotoff</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Foltzer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Mediastinal Mucormycosis: Case report, review of literature and treatment with continuous liposomal amphotericin B irrigation.</article-title>
            <source>Mycoses</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>9</issue>
            <fpage>739</fpage>
            <page-range>739-745</page-range>
            <pub-id pub-id-type="pmid">31044442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashyap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ghanchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cortez</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of Rhinocerebral Mucormycosis by Treatment of Cavernous Right Internal Carotid Artery Occlusion With Mechanical Thrombectomy: Special Case Presentation and Literature Review.</article-title>
            <source>Front Neurol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>264</fpage>
            <pub-id pub-id-type="pmid">30972005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valentine</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Morrissey</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Tacey</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Liew</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peleg</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Ananda-Rajah</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005 - 2016.</article-title>
            <source>BMC Infect Dis</source>
            <year>2019</year>
            <month>Mar</month>
            <day>21</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>274</fpage>
            <pub-id pub-id-type="pmid">30898090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marchesi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Passera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diliberto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Russello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Favalli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>In vitro activity of Amphotericin B against zygomycetes isolated from deep mycoses: a comparative study between incubation in aerobic and hyperbaric atmosphere.</article-title>
            <source>Med Mycol</source>
            <year>2012</year>
            <month>May</month>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>427</fpage>
            <page-range>427-32</page-range>
            <pub-id pub-id-type="pmid">21954953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31650.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyvernitakis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chamilos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kontoyiannis</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>811.e1</fpage>
            <page-range>811.e1-811.e8</page-range>
            <pub-id pub-id-type="pmid">27085727</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
